English

The board of directors of Biovitrum utilizes authorization to repurchase shares to secure the company's performance based, long-term share program for 2008

Report this content 

                        
The Annual General Meeting of Biovitrum resolved on 24 April 2008  to
issue 284,000 series C shares to secure that the company can  fulfill
its commitment according  to the performance  based, long-term  share
program for  2008 ("Share  Program  2008"). Furthermore,  the  Annual
General Meeting  resolved  to authorize  the  board of  directors  to
repurchase  all  issued  series  C  shares  for  a  price  per  share
corresponding to  the quota  value of  the Biovitrum  share, i.e.  in
total SEK 156,000. The series  C shares will thereafter be  converted
to common shares in  the number that is  required to secure  delivery
under the Share Program 2008.

The board  of directors  of  Biovitrum has  resolved to  utilize  the
authorization for  this purpose  and  to immediately  repurchase  all
issued series  C shares  in  accordance with  the resolution  by  the
Annual General Meeting on 24 April 2008. Biovitrum does currently not
hold own shares.

For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is a pharmaceutical company  with operations in Sweden  and
in the UK. The company markets a range of specialist pharmaceuticals.
Using  its  expertise  and  experience  Biovitrum  takes   scientific
innovation all the  way to  the market and  to specialist  indication
patients  with  significant  medical  need.  Research  expertise  and
capabilities include  development  and  production  of  biotechnology
therapeutics, as well  as small molecule  discovery and  development.
With revenues  of  approximately  SEK  1.3  billion  and  around  500
employees,  Biovitrum  is   a  significant  international   specialty
pharmaceutical player. Biovitrum's share is listed on the OMX  Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com


Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on December 23, 2008 at
08:30 a.m. CET.




                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links